EU officials question 'unjustified' cancer drug pricing from Aspen

15th May 2017 Uncategorised 0

Upon receiving information that Aspen Pharmacare has taken steep price increases on lifesaving cancer medications and threatened to pull its products in order to get the hikes through, European antitrust regulators have pledged to take a close look at the South African drugmaker’s business practices.

More: EU officials question 'unjustified' cancer drug pricing from Aspen
Source: fierce